Ausgabe 3/2023
Inhalt (20 Artikel)
A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition
Elizabeth I. Buchbinder, Anita Giobbie-Hurder, Patrick A. Ott
Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibit moderate effect on normal stem cells growth
Arshak R. Alexanian, Heidi Marie Stoellinger, Virginea de Araujo Farias, Alfredo Quiñones-Hinojosa
Prospective role of liquid biopsy for early screening in laryngeal cancer
Xiao-yang Gong, Hai-bing Chen, Zhao-yi Lu, Chan Zhu, Dong-sheng Chen, Xi Chen
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors
Anastasios Stathis, Anthony W. Tolcher, Judy S. Wang, Daniel J. Renouf, Lin-Chi Chen, Leah H. Suttner, Tomoko Freshwater, Andrea L. Webber, Tapan Nayak, Lillian L. Siu
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy
Nour Abuhadra, Ryan Sun, Roland L. Bassett Jr, Lei Huo, Jeffrey T. Chang, Mediget Teshome, Alyson R. Clayborn, Jason B. White, Elizabeth E. Ravenberg, Beatriz E. Adrada, Rosalind P. Candelaria, Wei Yang, Qingqing Ding, W. Fraser Symmans, Banu Arun, Senthil Damodaran, Kimberly B. Koenig, Rachel M. Layman, Bora Lim, Jennifer K. Litton, Alastair Thompson, Naoto T. Ueno, Helen Piwnica-Worms, Gabriel N. Hortobagyi, Vicente Valero, Debu Tripathy, Gaiane M. Rauch, Stacy Moulder, Clinton Yam
Brigatinib pharmacokinetics in patients with chronic hepatic impairment
Michael J. Hanley, David Kerstein, Meera Tugnait, Narayana Narasimhan, Thomas C. Marbury, Karthik Venkatakrishnan, Neeraj Gupta
Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients
Takehiro Tozuka, Noriko Yanagitani, Hiroshi Yoshida, Ryo Manabe, Shinsuke Ogusu, Ryosuke Tsugitomi, Hiroaki Sakamoto, Yoshiaki Amino, Ryo Ariyasu, Ken Uchibori, Satoru Kitazono, Masahiro Seike, Akihiko Gemma, Makoto Nishio
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors
Arvind Dasari, Erika P. Hamilton, Gerald S. Falchook, Judy S. Wang, Daneng Li, Max W. Sung, Caly Chien, Shivani Nanda, Christopher Tucci, Marjo Hahka-Kemppinen, Andrew Scott Paulson
Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study
Dong-Dong Jia, Yu Xu, Ting Li, Ji-Long Yang, Yong Chen, Tao Li
Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase
Chan Zhang, Xinan Zhao, Zifeng Wang, Tao Gong, Hong Zhao, Dong Zhang, Yuhu Niu, Xiaoning Li, Xuhua Zhao, Gaopeng Li, Xiushan Dong, Li Zhang, Chang Liu, Jun Xu, Baofeng Yu
Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials
Xiaoli Li, Yuyan Liu, Minhui Zhu, Cuixia He, Yuanyuan Xu, Jiaxiang Ding, Ying Wang, Rongfang Shan, Bingyan Liu, Yuzhou Ding, Jing Xie, Huan Zhou, Zhiqiang Wang, Yuanyuan Liu
Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non–small cell lung cancer patients
Xueyun Tan, Sufei Wang, Hui Xia, Hebing Chen, Juanjuan Xu, Daquan Meng, Zhihui Wang, Yan Li, Lian Yang, Yang Jin
HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial
Xiaoxue Zhu, Yanhua Ding, Qian Wang, Guiyu Yang, Liang Zhou, Qingyu Wang
Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles
Toshiyuki Tamai, Mamoru Narukawa
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
Gerald S Falchook, Jasgit Sachdev, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh M Mugundu, Suzanne Jenkins, Juliann Chmielecki, Suzanne Jones, David R Spigel, Melissa Johnson
Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors
Yang Luo, Ying Cheng, Chunjiao Wu, Hui Ye, Naihan Chen, Fan Zhang, Hua Wei, Binghe Xu
Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis
Takafumi Yamamoto, Kazuyuki Mizuno, Takanori Ito, Shinya Yokoyama, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Takuya Ishikawa, Akira Kanamori, Satoshi Yasuda, Hidenori Toyoda, Kenji Yokota, Tetsunari Hase, Naoki Nishio, Osamu Maeda, Makoto Ishii, Michihiko Sone, Yuichi Ando, Masashi Akiyama, Masatoshi Ishigami, Hiroki Kawashima
Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies
Li Ma, Juan Ma, Xin Sun, Honggang Liu
Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma
Shiqi Hu, Yaqin Liu, Qidong Yang, Lin Chen, Huizi Chai, Mingzhe Xiao, Chuang Qi, Wei Qiu
Correction to: A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies
Danny N. Khalil, Isabel Prieto González-Albo, Lee Rosen, Tom Lillie, Andrea Stacey, Lola Parfitt, Gerald A. Soff